Imfinzi

Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge
Endpoints
FDA
Advair
AstraZeneca
Imfinzi
clinical trials
Flag link:
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
Yahoo/Zacks.com
AstraZeneca
FDA
Imfinzi
non-small cell lung cancer
Flag link:
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
Endpoints
FDA
AstraZeneca
Imfinzi
lung cancer
Bavencio
Pfizer
Merck KGaA
Flag link:
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
BioPharma Dive
clinical trials
AstraZeneca
Mystic
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca plans new pivotal lung cancer trial with Incyte
AstraZeneca plans new pivotal lung cancer trial with Incyte
Yahoo/Reuters
AstraZeneca
Incyte
clinical trials
Imfinzi
epacadostat
lung cancer
Flag link:
What's Behind AstraZeneca's September Rebound?
What's Behind AstraZeneca's September Rebound?
Motley Fool
AstraZeneca
Imfinzi
Flag link:
NewLink inks deal with AstraZeneca to test Imfinzi combo
NewLink inks deal with AstraZeneca to test Imfinzi combo
BioPharma Dive
NewLink Genetics
AstraZeneca
Imfinzi
indoximod
metastatic pancreatic cancer
Flag link:
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
Fierce Pharma
ESMO
AstraZeneca
Imfinzi
lung cancer
Flag link:
AstraZeneca fights back in cancer with new hires, fast drug status
AstraZeneca fights back in cancer with new hires, fast drug status
Yahoo/Reuters
AstraZeneca
Imfinzi
immuno-oncology
Flag link:
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B
Fierce Pharma
AstraZeneca
Merck
Lynparza
Imfinzi
Flag link:
AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
Stat
AstraZeneca
Mystic
immuno-oncology
clinical trials
tremelimumab
Imfinzi
Flag link:
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Endpoints
investors
AstraZeneca
Pascal Soriot
Imfinzi
tremelimumab
immuno-oncology
clinical trials
Flag link:
AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next
AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next
Forbes
AstraZeneca
oncology
Imfinzi
Opdivo
Keytruda
Flag link:
AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC
AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC
Endpoints
AstraZeneca
clinical trials
durvalumab
Imfinzi
non-small cell lung cancer
Flag link:
Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town
Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town
Fierce Pharma
Pfizer
Merck KGaA
AstraZeneca
Bavencio
avelumab
bladder cancer
Imfinzi
FDA
Opdivo
Tecentriq
Flag link:
AstraZeneca's New Drug: Too Little, Too Late?
AstraZeneca's New Drug: Too Little, Too Late?
Seeking Alpha
AstraZeneca
Imfinzi
bladder cancer
Flag link: